---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011143"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:46:26.260698+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Passage Bio Q2 net loss narrows to $9.4M; cash runway into Q1 2027

## Summary
- Cash, cash equivalents and marketable securities: $57.6M as of June 30, 2025 vs $91.8M a year ago; runway into Q1 2027.
- Net loss of $9.4M ($2.96 per share) vs $16.0M ($5.09 per share) in Q2 2024 (adjusted for 1-for-20 reverse split).
- Completed dosing of FTD-GRN Cohort 2 in upliFT-D study; all four patients treated with PBFT02.
- Updated interim data: PBFT02 showed robust, durable CSF PGRN elevation and improved plasma NfL biomarker vs natural history.
- Amended upliFT-D protocol submitted to trial sites and health authorities; plan to enroll Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72).

## SEC filing metadata
- accession: 0001558370-25-011143
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837025011143/0001558370-25-011143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837025011143/pasg-20250812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011143
- JSON: https://secwatch.observer/filing/0001558370-25-011143.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.